9/21/2023

Janusmed kön och genus

Janusmed kön och genus – Ranitidin Apofri

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Ranitidin

Ranitidin

Klass : A

Visa all info

Skriv ut

Kontakta oss

Produkter

Visa alla produkter

Artonil, Inside, Inside Brus, Rani-Q, Ranilin, Ranitidi......

Artonil, Inside, Inside Brus, Rani-Q, Ranilin, Ranitidin Actavis, Ranitidin Apofri, Ranitidin Mylan, Ranitidin Sandoz, Ranitidin-ratiopharm, Ranitidine, Ranitidine Alliance, Stomacid, Zantac, Zantac Brus
ATC-koder

A02BA02

A02BA02
Substanser

ranitidin, ranitidinhydroklorid

ranitidin, ranitidinhydroklorid
Sammanfattning

De flesta studier har visat att ranitidin läker magsår i samma utsträckning hos kvinnor och män, men en studie har visat att kvinnor hade lägre återfallsfrekvens av magsår efter långtidsbehandling.

De flesta studier har visat att ranitidin läker magsår i samma utsträckning hos kvinnor och män, men en studie har visat att kvinnor hade lägre återfallsfrekvens av magsår efter långtidsbehandling.
Background

Pharmacokinetics and dosing
No sex differences in ranitidine pharmacokinetics were found in patients (8 men, 8 women) receiving 300 mg ranitidine [1]. One study has investigated if pharmacokinetic parameters of a single dose oral ranitidine differ in men and women in different phases of the menstrual cycle. Healthy volunteers (10 men, 10 women) received a single dose of 300 mg ranitidine. Differences were seen in women at different stages of the menstrual cycle. In the follicular phase distribution volume and total clearance was lower while AUC and maximum concentration was higher than in the luteal phase. Men had 56% higher AUC and 9% lower clearance than women in follicular phase [2]. Despite the pharmacokinetic differences of ranitidine, the clinical studies have shown the same effect with similar doses in men and women and no difference in dosing has been suggested [3].

Effects
A randomized, double-blind, placebo-controlled trial (99 men, 127 women) showed that 150 mg ranitidine for 48 weeks was more effective in maintaining healed gastric ulcers compared with placebo, in bo......

Visa hela bakgrundstexten

# Pharmacokinetics and dosing No sex differences in ranitidine pharmacokinetics were found in patients (8 men, 8 women) receiving 300 mg ranitidine [1]. One study has investigated if pharmacokinetic parameters of a single dose oral ranitidine differ in men and women in different phases of the menstrual cycle. Healthy volunteers (10 men, 10 women) received a single dose of 300 mg ranitidine. Differences were seen in women at different stages of the menstrual cycle. In the follicular phase distribution volume and total clearance was lower while AUC and maximum concentration was higher than in the luteal phase. Men had 56% higher AUC and 9% lower clearance than women in follicular phase [2]. Despite the pharmacokinetic differences of ranitidine, the clinical studies have shown the same effect with similar doses in men and women and no difference in dosing has been suggested [3]. # Effects A randomized, double-blind, placebo-controlled trial (99 men, 127 women) showed that 150 mg ranitidine for 48 weeks was more effective in maintaining healed gastric ulcers compared with placebo, in both men and women [4]. A case-controlled clinical trial in patients (63 men, 17 women) with giant gastric ulcer receiving ranitidine 300 mg daily for 8 weeks showed that healing rates were not related to patient’s sex [5]. Recurrence of duodenal ulcer after withdrawal of long-term treatment with ranitidine has been analyzed in several studies. A single-blind study found that women had lower relapse rates than men at 12 months (80% vs. 92%) [6] while other, randomized, placebo-controlled studies have not found patient’s sex to be a risk factor for recurrence [7, 8]. # Adverse effects No specific studies on relevant sex differences between men and women in adverse effects of ranitidine have been found. # Reproductive health issues Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Försäljning på recept

Visa hela försäljning på recept

Läkemedel innehållande ranitidin (ATC-kod A02BA02) köps huvudsakligen receptfritt och därför saknas könsspecifika användningsdata [9].
Referenser

Visa referenser

  1. Abad-Santos F, Carcas AJ, Guerra P, Govantes C, Montuenga C, Gómez E et al. Evaluation of sex differences in the pharmacokinetics of ranitidine in humans. J Clin Pharmacol. 1996;36:748-51.

  2. Flores Pérez J, Juárez Olguín H, Flores Pérez C, Pérez Guillé G, Guillé Pérez A, Camacho Vieyra A et al. Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. Chronobiol Int. 2003;20:485-94.

  3. Zantac (ranitidin). Summary of Product Characteristics. Swedish Medical Products Ageny; 2015.

  4. Sue SO, Dawson DM, Brown JA, Wood DR, Kleoudis CS. Effectiveness of ranitidine 150 mg at bedtime as maintenance therapy for healed gastric ulcers. Clin Ther. 1996;18:1175-83.

  5. Takemoto T, Sakaki N, Tsuneoka K, Namiki M, Ishikawa M, Oshiba S. Clinical usefulness of ranitidine in giant gastric ulcer. J Clin Gastroenterol. 1984;6:413-7.

  6. Lee FI, Samloff IM, Hardman M. Comparison of tri-potassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers. Lancet. 1985;1:1299-302.

  7. Koelz HR, Birchler R, Bretholz A, Bron B, Capitaine Y, Delmore G et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology. 1986;91:1198-205.

  8. Penston JG, Dixon JS, Boyd EJ, Wormsley KG. A placebo-controlled investigation of duodenal ulcer recurrence after withdrawal of long-term treatment with ranitidine. Aliment Pharmacol Ther. 1993;7:259-65.

  9. Conise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2021-11-18.]

  1. Abad-Santos F, Carcas AJ, Guerra P, Govantes C, Montuenga C, Gómez E et al. Evaluation of sex differences in the pharmacokinetics of ranitidine in humans. J Clin Pharmacol. 1996;36:748-51.
  2. Flores Pérez J, Juárez Olguín H, Flores Pérez C, Pérez Guillé G, Guillé Pérez A, Camacho Vieyra A et al. Effects of gender and phase of the menstrual cycle on the kinetics of ranitidine in healthy volunteers. Chronobiol Int. 2003;20:485-94.
  3. Zantac (ranitidin). Summary of Product Characteristics. Swedish Medical Products Ageny; 2015.
  4. Sue SO, Dawson DM, Brown JA, Wood DR, Kleoudis CS. Effectiveness of ranitidine 150 mg at bedtime as maintenance therapy for healed gastric ulcers. Clin Ther. 1996;18:1175-83.
  5. Takemoto T, Sakaki N, Tsuneoka K, Namiki M, Ishikawa M, Oshiba S. Clinical usefulness of ranitidine in giant gastric ulcer. J Clin Gastroenterol. 1984;6:413-7.
  6. Lee FI, Samloff IM, Hardman M. Comparison of tri-potassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers. Lancet. 1985;1:1299-302.
  7. Koelz HR, Birchler R, Bretholz A, Bron B, Capitaine Y, Delmore G et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology. 1986;91:1198-205.
  8. Penston JG, Dixon JS, Boyd EJ, Wormsley KG. A placebo-controlled investigation of duodenal ulcer recurrence after withdrawal of long-term treatment with ranitidine. Aliment Pharmacol Ther. 1993;7:259-65.
  9. Conise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2021-11-18.]
Uppdaterat

Litteratursökningsdatum: 6/12/2023

Litteratursökningsdatum: 6/12/2023